<DOC>
	<DOCNO>NCT01315873</DOCNO>
	<brief_summary>Patients myeloma either respond previous treatment return previous treatment give combination drug bendamustine bortezomib . The bortezomib bendamustine give use intravenous line ( IV ) day 1 4 cycle , bortezomib give first , dose bendamustine . Each cycle 28 day long , patient treat first week cycle 3 week 'off ' ( without treatment ) . Disease assessment perform day 22 cycle . Patients receive study drug disease progress withdrawn study . In study , bendamustine seem work well drug . Thus , study hop show combination bortezomib bendamustine activity relapsed/refractory myeloma .</brief_summary>
	<brief_title>Bortezomib Bendamustine Treat Relapsed/Refractory Myeloma</brief_title>
	<detailed_description>Patients relapse refractory myeloma measurable paraprotein serum urine measurable protein Freelite measurable disease plasmacytoma give combination bendamustine bortezomib cycle . Response rate ( PR well 2 cycle ) duration response assess . Therapy continue disease progression . The bendamustine would use day 1 , day 4 dosing schedule dose bortezomib take advantage chemosensitizing property bortezomib . This minimizes day treatment first week allow rebound blood count . This phase II trial dose reduction necessary . Bendamustine drug appear non-cross-resistant alkylating agent vitro vivo . Thus , hypothesize combination bortezomib bendamustine activity relapsed/refractory myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Voluntary write informed consent 2 . Age 18 year old 3 . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . 4 . Male subject agree use acceptable method contraception duration study . 5 . Diagnosis multiple myeloma base standard criterion follow : Major Criteria Plasmacytomas tissue biopsy Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) Monoclonal immunoglobulin spike serum electrophoresis ( IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL ) kappa lambda light chain excretion &gt; 1 g/day 24 hour urine protein electrophoresis Minor Criteria Bone marrow plasmacytosis ( 10 30 % plasma cell ) Monoclonal immunoglobulin present less magnitude give major criterion Lytic bone lesion Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL Any follow set criterion confirm diagnosis Multiple Myeloma : Any two major criterion 1 major plus 2 minor criterion . 6 . Measurable disease , define monoclonal immunoglobulin spike ( MSpike ) serum electrophoresis ≥1 g/dL and/or urine monoclonal immunoglobulin spike ≥200 mg/24 hour . Nonsecretors must measurable protein Freelite measurable disease plasmacytoma eligible . 7 . Patients must refractory myeloma define great 25 % increase Mprotein . They progress bortezomib . 8 . Karnofsky performance status ≥50 9 . Patients treat local radiotherapy without brief exposure steroid eligible . Patients require radiotherapy entry protocol defer radiotherapy complete least 4 week prior initiation study drug . 10 . Meets follow pretreatment laboratory criterion baseline ( Day 1 Cycle 1 , study drug administration ) Absolute neutrophil count ≥1 x 10^3/uL Platelet count ≥75 x 10^3/uL Hemoglobin ≥8.0 g/dL Calculated measure CrCL ≥ 40 mL/min AST ALT total bilirubin &lt; 3 x ULN 11 . Echocardiogram &gt; 50 % Ejection Fraction Patients meeting follow exclusion criterion register study : 1 . POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ) 2 . Plasma cell leukemia 3 . Receiving steroid daily medical condition , e.g. , asthma , systemic lupus erythematosis , rheumatoid arthritis 4 . Infection control antibiotic 5 . HIV infection . Patients provide consent HIV test accord institution 's standard practice . 6 . Known active hepatitis B C 7 . New York Hospital Association ( NYHA ) Class III IV heart failure , Echo MUGA ejection fraction &lt; 40 % ( know ) , EKG evidence acute ischemic disease 8 . Other serious medical psychiatric illness could potentially interfere completion treatment accord protocol 9 . Second malignancy require treatment last 3 year 10 . Patient calculate measured creatinine clearance &lt; 40 mL/min within 14 day enrollment 11 . Patient &gt; Grade 2 peripheral neuropathy within 14 day enrollment 12 . Patient hypersensitivity bortezomib , boron mannitol bendamustine 13 . Positive pregnancy test woman childbearing potential subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum betaa human chorionic gonadotropin test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . 14 . Patient receive investigational drug 14 day enrollment 15 . Serious medical psychiatric illness likely interfere participation clinical study . 16 . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>myeloma</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>relapse myeloma</keyword>
	<keyword>refractory myeloma</keyword>
</DOC>